LRMR Larimar Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why LRMR matters now
Larimar Therapeutics, Inc. (LRMR) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.28 with +3.63% on the session and $366.3M in market capitalization; recent performance reads 1-month +9.31% and YTD -4.46%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-29.6M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -42.2%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Hamilton Thomas Edward filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.96
P/S
0.00
EV/EBITDA
-0.83
DCF Value
$1.06
FCF Yield
-42.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-134.1%
ROA
-79.6%
ROIC
-106.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-29.6M | $-0.35 |
| Q4 2025 | $0.00 | $-62.5M | $-0.73 |
| FY 2025 | $0.00 | $-165.7M | $-2.27 |
| Q3 2025 | $0.00 | $-47.7M | $-0.61 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.82
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.